Autonomix develops a first-in-class platform technology that provides real-time, intra-procedural nerve mapping for precision denervation. This minimally invasive approach allows physicians to sense nerve activity through the vascular system, guide energy delivery, and confirm effective ablation. The technology aims to expand therapeutic possibilities across cardiology, interventional pain management, and gastroenterology by enabling targeted, nerve-specific treatment.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for treating pain in pancreatic cancer patients, such as opioids and invasive ethanol injections, often provide limited relief and can lead to significant side effects. Existing nerve ablation technologies lack the sensitivity needed to precisely target the nerves responsible for transmitting pain signals. This imprecision can result in ineffective treatment and continued suffering for patients.
Solution
Autonomix Medical is developing a precision-guided radio frequency (RF) ablation system designed to identify, target, and ablate overactive nerves with significantly greater sensitivity than existing technologies. The system utilizes a custom antennae array capable of detecting electrical nerve signaling with increased sensitivity, enabling physicians to pinpoint and target specific nerves throughout the body implicated in various diseases. This minimally invasive, transvascular procedure aims to provide effective pain relief for pancreatic cancer patients, reducing their reliance on opioids and improving their overall quality of life. The system also verifies that nerve signaling has stopped post-ablation.
Target Audience
The primary target audience includes pancreatic cancer patients suffering from pain not relieved by current methods, as well as physicians specializing in pain management and therapeutic electrophysiology.
Features
- Custom antennae array capable of detecting electrical nerve signaling with increased sensitivity.
- Precision-guided radio frequency (RF) ablation technology for targeted nerve ablation.
- Minimally invasive, transvascular procedure.
- Real-time data feedback to physicians for precise targeting of overactive nerves.
- Verification system to confirm nerve signaling has ceased post-ablation.
- Potential application across a wide spectrum of diseases, including chronic pain management, cardiovascular conditions, and pulmonary conditions.